Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 7/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.35 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6052881 | 0.99 | HPGD (0.36) | HPGDCYP2C9KDM4EPOLBGAA | |
| SCHEMBL6052901 | 0.88 | TSHR (0.41) | HPGDKDM4EPOLBGAAMAPT | |
| SCHEMBL29729255 | 0.70 | CYP2C9 (0.51) | HPGDCYP2C9KDM4EPOLBGAA | |
| SCHEMBL6769735 | 0.70 | ALDH1A1 (0.31) | KDM4EGAAALDH1A1 | |
| SCHEMBL5477247 | 0.67 | HPGD (0.54) | HPGDPOLBALDH1A1HSP90AA1 | |
| SCHEMBL16050669 | 0.66 | HPGD (0.53) | HPGDKDM4EALDH1A1 | |
| SCHEMBL746063 | 0.66 | HTT (0.54) | HPGDGAAALDH1A1L3MBTL1 | |
| SCHEMBL743907 | 0.66 | HPGD (0.53) | HPGDKDM4EALDH1A1 | |
| SCHEMBL15516376 | 0.65 | PIM1 (0.41) | KDM4EGAAMAPTALDH1A1GRM2 | |
| SCHEMBL1583125 | 0.63 | SMN1; SMN2 (0.59) | HPGDKDM4EPOLBGAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020132806-A1 | 7-[(4'-trifluoromethyl-biphenyl-2-carbonyl)amino]-quinoline-3-carboxylic acid amides, and methods of inhibiting the secretion of apolipoprotein B | RUGGERI ROGER (US) | 2002-09-19 | — | — | US | claimed |
| US-6369075-B1 | 7[4′-trifluoromethyl-biphenyl-2-carbonyl)amino]-quinoline-3-carboxylic acid amides, and method of inhibiting the secretion of apolipoprotein B | PFIZER, INC. | 2002-04-09 | — | — | US | claimed |
| EP-1099701-A1 | 7-[(4'-Trifluoromethyl-biphenyl-2-carbonyl)amino]-quinoline-3-carboxylic acid amides, and methods of inhibiting the secretion of apolipoprotein B | Pfizer Products Inc. (US) | 2001-05-16 | — | — | EP | claimed |
| EP-1157695-B1 | Method of treating obesity using a neurotensin receptor ligand | PFIZER PROD INC (US) | 2006-06-28 | — | — | EP | disclosed |
| US-6734175-B2 | ADMINISTERING TO AN OBESE PATIENT OR ONE AT RISK OF BECOMING OBESE A THERAPEUTIC COMPOUND THAT ATTENUATES THE BINDING OF AGOUTI-RELATED PROTEIN TO MELANOCORTIN RECEPTORS, FREE OF BINDING OF ALPHA-MELANOCYTE STIMULATING HORMONE TO RECEPTOR | PFIZER INC. | 2004-05-11 | — | — | US | disclosed |
| US-6713489-B2 | TREATMENT OF ATHEROSCLEROSIS, OBESITY, DIABETES, HYPERLIPIDEMIA, HYPERLIPOPROTEINEMIA, HYPERCHOLESTEROLEMIA, HYPERTRIGLYCERIDEMIA, HYPOALPHALIPOPROTEINEMIA, PANCREATITIS, MYOCARDIAL INFARCTION, STROKE, RESTENOSIS, OR SYNDROME X | PFIZER INC | 2004-03-30 | — | — | US | disclosed |
| US-6699832-B2 | MAY CONTAIN ANOTHER COMPOUND TO TREAT DIABETES, SEXUAL DYSFUNCTION, ATHEROSCLEROSIS, INSULIN RESISTANCE, IMPAIRED GLUCOSE TOLERANCE, HYPERCHOLESTEROLEMIA OR HYPERTRIGLYCERIDEMIA | PFIZER INC. | 2004-03-02 | — | — | US | disclosed |
| US-20030040535-A1 | Tetrazole compounds as thyroid receptor ligands | ASPNES GARY E (US) | 2003-02-27 | — | — | US | disclosed |
| US-20020198152-A1 | Treatments for obesity and methods for identifiying compounds useful for treating obesity | HADCOCK JOHN R (US) | 2002-12-26 | — | — | US | disclosed |
| US-20020132806-A1 | 7-[(4'-trifluoromethyl-biphenyl-2-carbonyl)amino]-quinoline-3-carboxylic acid amides, and methods of inhibiting the secretion of apolipoprotein B | RUGGERI ROGER (US) | 2002-09-19 | — | — | US | disclosed |
| US-6451783-B1 | Treatments for obesity and methods for identifying compounds useful for treating obesity | PFIZER INC. | 2002-09-17 | — | — | US | disclosed |
| US-6441015-B2 | OBESITY, ANTIDIABETIC AGENTS, CARDIOVASCULAR DISORDERS | PFIZER INC. | 2002-08-27 | — | — | US | disclosed |
| US-20020065277-A1 | Treatments for obesity and methods for identifiying compounds useful for treating obesity | HADCOCK JOHN R (US) | 2002-05-30 | — | — | US | disclosed |
| US-6369075-B1 | 7[4′-trifluoromethyl-biphenyl-2-carbonyl)amino]-quinoline-3-carboxylic acid amides, and method of inhibiting the secretion of apolipoprotein B | PFIZER, INC. | 2002-04-09 | — | — | US | disclosed |
| US-20020006946-A1 | Tetrazole compounds as thyroid receptor ligands | PFIZER INC. | 2002-01-17 | — | — | US | disclosed |
| US-20010046956-A1 | Methods of treating obesity using a neurotensin receptor ligand | HADCOCK JOHN R (US) | 2001-11-29 | — | — | US | disclosed |
| EP-1157695-A1 | Method of treating obesity using a neurotensin receptor ligand | Pfizer Products Inc. (US) | 2001-11-28 | — | — | EP | disclosed |
| EP-1127882-A1 | Tetrazole compounds as thyroid receptor ligands | Pfizer Products Inc. (US) | 2001-08-29 | — | — | EP | disclosed |
| EP-1125579-A2 | Uses of agrp-melanocortin receptor binding modulating compounds | Pfizer Products Inc. (US) | 2001-08-22 | — | — | EP | disclosed |
| EP-1099701-A1 | 7-[(4'-Trifluoromethyl-biphenyl-2-carbonyl)amino]-quinoline-3-carboxylic acid amides, and methods of inhibiting the secretion of apolipoprotein B | Pfizer Products Inc. (US) | 2001-05-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030040535-A1 | Tetrazole compounds as thyroid receptor ligands | THRA, TSHR, THRB | HPGD 2141/4885CYP2C9 47/4885KDM4E 3605/4885 |
| US-20020132806-A1 | 7-[(4'-trifluoromethyl-biphenyl-2-carbonyl)amino]-quinoline-3-carboxylic acid amides, and methods of inhibiting the secretion of apolipoprotein B | APOB, CETP, PNLIP | HPGD 2015/4885CYP2C9 937/4885KDM4E 3538/4885 |
| US-20020006946-A1 | Tetrazole compounds as thyroid receptor ligands | TSHR, THRA, THRB | HPGD 1957/4885CYP2C9 47/4885KDM4E 3587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.